ClinicalTrials.gg
TerminatedNCT00003056Updated May 6, 2021

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

A Phase 3 interventional study of cyclosporine and cyclosporine and methotrexate in Leukemia, Lymphoma and Graft Versus Host Disease, sponsored by Baxalta now part of Shire. Terminated at 13 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Supportive care

Why this study was terminated
Interim analysis indicated study should be terminated

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Apr 1997, registered Nov 1999).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies testing cyclosporine in Leukemia — 1 open to participants now, 1 under way, none of them phase 3. Cyclosporine · Leukemia.

Enrollment
8th of 32
105 · median 45
Started
1997
with 1 other
Phase 3
5 of 35
none open now
Registered
1st of 35
by date
Lead sponsor
1 of 35
Baxalta now part of Shire

Among the 35 studies testing cyclosporine in Leukemia, this one is the 8th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 1997, is one of 5 in phase 3, and was the 1st registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

1 of the 35 studies testing cyclosporine in Leukemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing cyclosporine in Leukemia, or all of them as a file.
02

Study summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues.

PURPOSE: Randomized phase III trial to compare the effectiveness of cyclosporine plus methotrexate with cyclosporine plus T cell depletion for prevention of graft-versus-host disease during peripheral stem cell transplantation in patients who have advanced leukemia or lymphoma who are eligible for transplanted peripheral stem cells from a donor.

Read the detailed description

OBJECTIVES: I. Demonstrate that the graft versus host disease (GVHD) prophylactic regimen consisting of T-cell depletion and cyclosporine results in less toxicity than the control regimen of methotrexate and cyclosporine in recipients of peripheral blood stem cell transplants. II. Monitor safety of the two regimens in order to assure that the treatment regimen dose not result in any increase in serious or unexpected toxicities, does not compromise the efficacy of GVHD prophylaxis, and does not compromise the efficacy of the disease therapy.

OUTLINE: This is a multicenter, controlled, randomized trial. Patients are assigned to high or low risk groups and randomized to the control or treatment arms. Patients are stratified by risk group and by site. Mobilization, apheresis, and successful cryopreservation of the minimum number of CD34 cells for transplant has to be achieved prior to initiating cytoreductive therapy. Following intensive cytoreductive therapy, patients receive either unselected peripheral blood stem cells (PBSC) together with the control graft versus host disease (GVHD) prophylaxis regimen or CD34+ cells isolated from PBSC with cyclosporine. In the control group, GVHD prophylaxis consists of two drug therapies, cyclosporine and methotrexate. The cyclosporine is administered first by IV continuous infusion and then later orally, twice a day, in decreasing increments for 180 days. Methotrexate is administered by IV on days 1, 3, 6, and 11. Cyclosporine is discontinued after day +180 if there is no evidence of GVHD. In the treatment group, GVHD prophylaxis consists of T cell depletion of the transplant product using the Isolex positive selection procedure (Isolex selected CD34+ cells) and cyclosporine. The cyclosporine is administered at the same doses and increments as in the control group. In cases where there still is acute or chronic GVHD, the patient is given the appropriate salvage regimens. Patients are followed monthly for 6 months after transplant, and then for 2 years to monitor relapses.

PROJECTED ACCRUAL: There will be 200 patients accrued (100 in each arm) in this study.

03

Conditions studied

  • Leukemia
  • Lymphoma
  • Graft Versus Host Disease

Keywords

  • recurrent adult diffuse small cleaved cell lymphoma
  • adult acute myeloid leukemia in remission
  • recurrent grade 2 follicular lymphoma
  • accelerated phase chronic myelogenous leukemia
  • adult acute lymphoblastic leukemia in remission
  • recurrent grade 1 follicular lymphoma
  • recurrent adult lymphoblastic lymphoma
  • recurrent marginal zone lymphoma
  • chronic phase chronic myelogenous leukemia
  • recurrent small lymphocytic lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent adult Hodgkin lymphoma
  • recurrent adult acute lymphoblastic leukemia
  • recurrent adult immunoblastic large cell lymphoma
  • graft versus host disease
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent mantle cell lymphoma
  • splenic marginal zone lymphoma
  • recurrent adult acute myeloid leukemia
  • extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  • recurrent adult diffuse large cell lymphoma
  • nodal marginal zone B-cell lymphoma
  • recurrent adult Burkitt lymphoma
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS: - Acute lymphocytic leukemia (ALL) with documented chemosensitivity (complete response [CR], partial response [PR], or minor response [MR]) in first or second remission, first or second relapse, or high risk ALL with Ph positive 9/22 translocation; OR - Acute myelogenous leukemia (AML) with documented chemosensitivity (CR, PR, or MR) in first or second remission, or first or second relapse; OR - Chronic myelogenous leukemia (CML), chronic or accelerated, that is not in blast crisis; OR - Hodgkin's disease or non-Hodgkin's lymphoma with documented chemosensitivity in first or second relapse Consenting human lymphocyte antigen (HLA)-identical related donor required No active central nervous system (CNS) or skin leukemia involvement No disease that requires additional mediastinal radiation

PATIENT CHARACTERISTICS: Age: 18-55 Performance status: 70-100% : Greater than 8 weeks Hematopoietic: Not specified Hepatic: less than 1.5 times normal serum glutamate oxalo-acetate transaminase () less than 2 times normal Renal: Creatinine less than 1.5 times normal Cardiovascular: at rest at least 40% or within normal range Pulmonary: diffusing capacity of the lung for carbon monoxide (DLCO) greater than 45% of predicted or within normal range Other: negative At least 2 weeks since any active infection requiring intravenous treatment with antifungal, antibacterial or antiviral agents with the exception of coagulase negative staphylococcal line infection No coexisting medical problems that would significantly increase the risk of the transplant procedure Not pregnant or nursing

PRIOR CONCURRENT THERAPY: No more that 2 prior therapy regimens Biologic therapy: No prior autologous or allogeneic bone marrow or peripheral blood stem cell transplant Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Prior radiation therapy subject to dose requirements Surgery: Not specified Other: At least 2 weeks since intravenous treatment with antifungal, antibacterial or antiviral agents, except for treatment of coagulase negative staphylococcal infection of an IV or central line

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Unselected peripheral blood haemopoietic stem cells (PBSC)

    Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control

    Drug: cyclosporine and methotrexate

  • Experimental
    CD34+ cells isolated from PBSC

    CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine

    Drug: cyclosporine

Interventions

06

What researchers measure

Primary outcomes

  1. Time to neutrophil engraftment

    Time frame: Month 1, post-transplant

  2. Time to neutrophil engraftment

    Time frame: Month 2, post-transplant

  3. Time to neutrophil engraftment

    Time frame: Month 3, post-transplant

  4. Time to neutrophil engraftment

    Time frame: Month 4, post-transplant

  5. Time to neutrophil engraftment

    Time frame: Month 5, post-transplant

  6. Time to neutrophil engraftment

    Time frame: Month 6, post-transplant

07

Study locations

13 sites
  • Los Angeles, California, United States
  • Jacksonville, Florida, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Lawrence, Kansas, United States
  • Saint Paul, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Hackensack, New Jersey, United States
  • Pittsburgh, Pennsylvania, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Adelaide, South Australia, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 1997 to primary completion in Jun 2003, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 1999
First posted
May 24, 2004
StartActual
Apr 1, 1997
Primary completionActual
Jun 1, 2003
CompletionActual
Jun 1, 2003
Last update
May 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00003056
Responsible party
Sponsor
First posted
May 24, 2004
Start date
Apr 1, 1997
Primary completion
Jun 1, 2003
Completion
Jun 1, 2003
Last update
May 6, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion